sarepta therapeutics elevidys - Search News

News

Sarepta Therapeutics, FDA

The Boston Globe · 3d

Sarepta soars after FDA says some patients can get Elevidys

Sarepta Therapeutics Inc. shares rose sharply early Tuesday after US regulators reversed course and recommended that patients who can walk be allowed to take its gene therapy Elevidys again.

Reuters on MSN · 4d

Sarepta resumes shipping of gene therapy Elevidys to patients who can walk

Sarepta Therapeutics said on Monday it will resume shipping of its muscular disorder gene therapy to patients who can walk, sending the company's shares 59% higher in extended trading.

Investopedia on MSN · 3d

Sarepta Therapeutics Stock Surges as FDA Allows Elevidys Sales to Resume

Key Takeaways Sarepta Therapeutics shares jumped in intraday trading Tuesday after the company said it was resuming shipments of one of its drugs.Sales were paused last week as the FDA reviewed a third death of a patient who was taking its muscular dystrophy medication Elevidys.

Fierce Pharma4d

FDA takes U-turn on Sarepta's Elevidys, backing Duchenne gene therapy again in ambulatory patients

Monday, the FDA said Sarepta may resume treating ambulatory DMD patients with Elevidys. The recommendation comes just 10 days ...

4don MSN

Sarepta rises 2%; Barclays downgrades to underweight on liquidity and Elevidys concerns

Sarepta Therapeutics (NASDAQ:SRPT) shares dropped sharply premarket on Monday before paring losses as Barclays revised its ...

7d

Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the ...

Fierce Pharma11d

Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market

As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head, the biotech is standing firm ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results